WebApr 11, 2024 · Elusys Therapeutics. On December 21, 2024, NightHawk announced that it had signed a definitive merger agreement to acquire Elusys Therapeutics which was subsequently closed on April 20, 2024. Elusys is a commercial-stage biodefense company and manufacturer of obiltoxaximab (Anthim), a treatment for anthrax inhalation that is … WebElusys General Information. Description. Developer of antibody therapeutics designed to treat infectious life-threatening infectious diseases. The company's therapeutics treat anthrax exposure following a natural or intentional release of anthrax spores and also treat biodefense, cancer, lupus nephritis, infectious diseases, and thrombosis, enabling …
Board of Directors - Elusys
WebElusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services January 31, 2024 2024 WebElusys Therapeutics is a subsidiary of NightHawk Biosciences, an ecosystem of companies dedicated to developing and deploying novel biodefense solutions to enable … Elusys was also contracted as of 2024 to deliver ANTHIM to the Public Health … Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, its … The following resources contain information regarding anthrax infection, guidelines … Please call 1-844-808-0222 or email [email protected] General … At Emergo Therapeutics he worked on a novel immunological treatment for … He is also a board member of Synthetic Biologics, Inc., a clinical stage company … David F. Lasseter was the Deputy Assistant Secretary of Defense for Countering … Elusys Publications. Nighthawk Publications. 2024. ... September 2016 … google scholar alexey miroshnikov
Obiltoxaximab Receives Marketing Authorization From European …
WebApr 11, 2024 · Elusys Therapeutics. On December 21, 2024, NightHawk announced that it had signed a definitive merger agreement to acquire Elusys Therapeutics which was subsequently closed on April 20, 2024 ... WebCFO at Elusys Therapeutics, Inc. Basking Ridge, New Jersey, United States. 355 followers 354 connections. Join to view profile Elusys … WebCompany Description: Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. The company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim was approved by the US FDA in 2016 to treat and prevent inhaled anthrax; Elusys received federal funding for its research efforts on the drug. chicken craft preschool